Crh responsive genes in cns
AssigneeJanssen Pharmaceutica NV
InventorsPieter Peeters, Hinrich Wilhelm Gohlmann, Sigrid Swagemakers, Stefan Kass, Thomas Horst Steckler, Frederik Fierens
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to therapy and diagnosis of depression. In particular this invention relates to the polypeptides as well as to the polynucleotides encoding these polypeptides, wherein said polypeptides are shown to play a central role in mediating the endocrine response to corticotropin releasing hormone. These polypeptides and polynucleotides are useful in the diagnosis, treatment and/or prevention of depression.
Claims31
A method of diagnosing a CRH induced gene expression profile in an individual said method comprising;
- a) obtaining a biological sample of said individual;
- and
- b) determine the level of gene transcription of a gene comprising a nucleic acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID NO.5, SEQ ID NO.6, SEQ ID No.7, SEQ ID No.8, SEQ ID NO.9, SEQ ID 11, SEQ ID NO.13, SEQ ID NO.15, SEQ ID NO.17, SEQ ID NO.19, SEQ ID NO.21, SEQ ID NO.23, SEQ ID No.25, SEQ ID No.26, SEQ ID No.27, SEQ ID No.28, SEQ ID No.29, SEQ ID No.30, SEQ ID No.31, SEQ ID NO.32, SEQ ID NO.34, SEQ ID NO.36, SEQ ID No.38 and SEQ ID No.40.
A method of diagnosing a CRH induced gene expression profile in an individual said method comprising;
- a) obtaining a biological sample of said individual;
- and
- b) determine the amount of at least one protein that modulates corticotropin releasing hormone (CRH) signaling in said biological sample;
- whereby the protein that modulates corticotropin releasing hormone (CRH) signaling is being selected from the group consisting of SEQ ID NO.10, SEQ ID 12, SEQ ID NO.14, SEQ ID NO.16, SEQ ID NO.18, SEQ ID NO.20, SEQ ID NO.22, SEQ ID NO.24, SEQ ID NO.33, SEQ ID NO.35, SEQ ID NO.37, SEQ ID No.39 and SEQ ID No.41.
(canceled)
A method for identifying a compound capable to alter the CRH signalling response activity in a cell, said method comprising;
- a) contacting a cell which expresses at least one protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO.10, SEQ ID 12, SEQ ID NO.14, SEQ ID NO.16, SEQ ID NO.18, SEQ ID NO.20, SEQ ID NO.22, SEQ ID NO.24, SEQ ID NO.33, SEQ ID NO.35, SEQ ID NO.37, SEQ ID No.39 and SEQ ID No.41, with said test compound;
- and
- b) compare the CRH response activity of said cell in the presence and absence of said compound.
An isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6, SEQ ID No.7, SEQ D No.8, SEQ ID No.25, SEQ ID No.26, SEQ ID No.27, SEQ ID No.28, SEQ ID No.29, SEQ ID No.30 and SEQ ID No.31, for use as a marker of CRH signaling in a cell.
An isolated polynucleotide consisting of a nucleic acid sequence selected from the group consisting of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6, SEQ ID No.7, SEQ D No.8, SEQ ID No.25, SEQ ID No.26, SEQ ID No.27, SEQ ID No.28, SEQ ID No.29, SEQ ID No.30 and SEQ ID No.31, for use as a marker of CRH signaling in a cell.
Dependencies are inferred from the claim text.